Talis Biomedical Corp
NASDAQ:TLIS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
T
|
Talis Biomedical Corp
NASDAQ:TLIS
|
90m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.4B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
127.3B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.2B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Talis Biomedical Corp
Glance View
Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2021-02-12. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The firm is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The firm is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Talis Biomedical Corp is 95.1%, which is above its 3-year median of 30.8%.
Over the last 2 years, Talis Biomedical Corp’s Gross Margin has increased from -7.6% to 95.1%. During this period, it reached a low of -74.4% on Dec 31, 2022 and a high of 98.1% on Dec 31, 2023.
